Treating the mother - Protecting the unborn: The safety of hypoglycemic drugs in pregnancy

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 3, 2008, Pages 191-196

  Klieger, Chagit ^a   Pollex, Erika ^b   Koren, Gideon ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Diabetes mellitus; Gestational diabetes; Glyburide; Insulin analogs; Metformin; Oral hypoglycemic drugs; Pregnancy

Indexed keywords

GLIBENCLAMIDE; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC PATIENT; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FETUS OUTCOME; GLYCEMIC CONTROL; HUMAN; MOTHER; NONHUMAN; OUTCOME ASSESSMENT; PLACENTA; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; TERATOGENICITY;

DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY IN DIABETICS; PRENATAL CARE;

EID: 39749084441     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050801929653     Document Type: Conference Paper

References (31)

1. Homko CJ, Reece AE. Insulins and oral hypoglycemic agents in pregnancy. JMatern Fetal Neonatal Med 2006;19(11):679-686.
2. American College of Obstetricians and Gynecologists. Pregestational diabetes mellitus, Practice Bulletin no 60. 2005.
3. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: A meta-analysis. Can J Clin Pharmacol 2003;10(4):179-183.
4. Xiong X, Saunders LD, Wang FL, Demianczuk NN. Gestational Diabetes mellitus: Prevalence, risk factors, maternal and infant outcomes. Int J Gynecol Obstet 2001;75:221-228.
5. Cohen RM, Sperling MA, Cutfield WS, Mimouni F, Khoury JC. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: Its role in fetal macrosomia. N Engl J Med 1990;323(5):309-315.
6. Slieker LJ, Brooke GS, Di Marchi RD. Modifications in the B10 and B26-30 regions of the B chain of human insulins alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 1997;40(Suppl. 2):S54-61.
7. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49(6):999-1005.
8. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46(2):265-270.
9. Boskovic R, Feig D, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: In vitro perfusion studies. Diabetes Care 2003;26:1390-1394.
10. Diamond T, Kormas N. Possible adverse fetal effects of insulin lispro. N Engl J Med 1997;337:1009.
11. Anderson J, Bastyr E, Wishner K. Response to Diamond and Kormas. N Engl J Med 1997;337:1009-1012.
12. Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. QJM 2001;94(5):255-260.
13. Wyatt JW, Frias JL, Hoyme HE, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Seely EW, Kerr L, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 2005;22(6):803-807.
14. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25(5):876-882.
15. Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med 2007;10:1129-1135.
16. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23(8):1130-1136.
17. Hoffman T, Horstmann G, Stammberger I. Evaluation of reproductive toxicity and embryo toxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002;21(3):181-189.
18. Woolderink JM, van Loon AJ, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 2005;28(10):2594-2595.
19. Price N, Bartlett C, Gillmer MD. Use of insulin glargine during pregnancy: A case-control pilot study. BJOG 2007;114:453-457.
20. Druckmann R, Rohr UD. IGF-1 in gynecology and obstetrics: Update 2002. Maturitas 2002;41(Suppl. 1):S65-S83.
21. Elliot BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans: A model of human placental drug transfer. Am J Obstet Gynecol 1994;171(3):653-660.
22. Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental ABC transporters: Implications in fetal drug exposure. Placenta 2006;27(11-12):1096-1102.
23. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343(16):1134-1138.
24. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003;63(18):1879-1894.
25. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005;83(5):1575-1578.
26. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: Prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004;19(3):510-521.
27. Kovo M, Weissman A, Gur D, Levran D, Rotmensch S, Glezerman M. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med 2006;19(7):415-419.
28. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Siene L, Wang P. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on continued metformin throughout pregnancy. Human Reprod 2004;(19):1323-1330.
29. Gilbert C, Valois M, Koren G. Pregnancy outcome after first trimester exposure to metformin: A meta-analysis. Fertil Steril 2006;86(3):658-663.
30. Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M, Dikici M, Yaris E. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005;19(4):563-564.
31. Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 2006;195(1):270-274.